In the current study, we tested a large series of women with diagnosed LBC fulfilling the HLBC clinical criteria, aiming to assess the frequency of germline variants in the CDH1 gene, genomic inactivation in matched tumor samples, and disease-free and overall survival. The gene discussed is CDH1; the disease is neoplasm.